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ABSTRACT
Aims To examine variability and effectiveness of interventions provided to comparator (control) groups in smoking ces-
sation trials.Methods Systematic review with meta-analysis of randomized controlled trials (RCTs) of behavioral inter-
ventions for smoking cessation, with or without stop-smoking medication. We searched the Cochrane Tobacco Addiction
Group Specialized Register for RCTs with objective outcomes measured at ≥ 6 months. Study authors were contacted to
obtain comprehensive descriptions of their comparator interventions. Meta-regression analyses examined the relation-
ships of smoking cessation rates with stop-smoking medication and behavior change techniques. Results One hundred
and four of 142 eligible comparator groups (n= 23706) had complete data andwere included in analyses. There was con-
siderable variability in the number of behavior change techniques delivered [mean = 15.97, standard deviation
(SD) = 13.54, range = 0–45] and the provision of smoking cessation medication (43% of groups received medication)
throughout and within categories of comparator groups (e.g. usual care, brief advice). Higher smoking cessation rates
were predicted by provision of medication [B= 0.334, 95% confidence interval (CI) = 0.030–0.638, P= 0.031] and num-
ber of behavior change techniques included (B = 0.020, 95% CI = 0.008–0.032, P< 0.001). Modelled cessation rates in
comparator groups that received themost intensive support were 15 percentage points higher than those that received the
least (23 versus 8%). Conclusions Interventions delivered to comparator groups in smoking cessation randomized con-
trolled trials vary considerably in content, and cessation rates are strongly predicted by stop-smokingmedication and num-
ber of behavior change techniques delivered.
Keywords Behavior change techniques, comparator group, control group, meta-analysis, meta-regression, smoking
cessation, systematic review.
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INTRODUCTION
Tobacco smoking is a leading cause of prematuremortality,
disease and health-care expenditures [1,2]. Numerous
smoking cessation interventions have been developed and
their evidence synthesized in systematic reviews, including
multiple Cochrane reviews [3–11]. The evidence generated
has informed smoking cessation guidelines and health-care
services and helped numerous people to quit smoking
[12,13]. Accurate evidence can optimize the effectiveness
of these interventions and ensure that services offered are
those which are most cost-effective.
The effectiveness of smoking cessation interventions
is commonly determined by comparing them with an
active control. As such, the observed effect sizes will be a
function of the effectiveness of the intervention provided
to the experimental group, but also the intervention pro-
vided to the corresponding control group, or ‘comparator
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group’,1 as well as of other variables. Study aims vary from
trial to trial, and the type of comparator employed should
covarywith these aims [14]. At themostminimal, compar-
ator groups receive no support and simply report their out-
comes (which, arguably, could be considered very brief
support in itself) [15]. At the most intensive, comparator
groups might receive many counselling sessions. System-
atic reviews of behavioral interventions tend to either ig-
nore the variability in comparator interventions or try to
address it by organizing comparator groups into broad cat-
egories, such as no behavioral support, self-help [e.g. pam-
phlets, self-directed workbooks, applications (apps)], brief
advice/counselling (e.g. a short, typically less than 30 mi-
nutes, amount of advice/counselling), extended counsel-
ling (longer, often multiple sessions, of counselling), usual
care (any support already typically delivered in practice)
and/or some combination of these categories [3–8]. This
approach might not fully account for the variability be-
tween comparator groups, as evidence from other areas
shows that intervention content delivered to ‘usual care’
groups can vary considerably between trials [16]. In a pre-
vious systematic reviewofHIVmedication adherence inter-
ventions, this variability in usual care content explained up
to 34% points differences in the clinical outcomes observed
in the comparator groups and influenced trial effect sizes
[16,17]. This suggests that, without accounting for the dif-
ferences in the intervention content provided to compara-
tor groups, it might not be possible to directly synthesize
experimental intervention effects from these trials. Further,
for readers of these trials—such as those assessingwhether
a given intervention will improve outcomes over their cur-
rent practice—it might also not be possible to interpret,
compare or generalize the results.
The present aim was to examine the variability and ef-
fectiveness of comparator intervention content in a much
larger and more heterogeneous body of randomized con-
trolled trials (RCTs) of behavioral interventions for smoking
cessation among adults [18]. Based on previous research,
our pre-registered (https://osf.io/24pzj/) primary hypothe-
ses were that provision of pharmacological support (i.e.
smoking cessation medication) and behavioral support
[i.e. higher number of smoking cessation behavior change
techniques (BCTs)] [19,20] would vary between compara-
tor groups and predict higher smoking cessation. We also
predicted that BCTs delivered in a personalized manner
would be more effective than those delivered in a non-
personalized manner (i.e. a one-size-fits-all approach). Sec-
ondary hypotheses were that behavioral support delivered
by a person would be more effective than support delivered
in writing (digital and/or print), that more adjuvant sup-
port to engage participants with the intervention would
predict higher cessation rates and that, among those who
received medication, more adjuvant support to increase
medication adherencewould predict higher cessation rates.
METHODS
Reporting standards
This study is part of a larger systematic review of behav-
ioral smoking cessation trials IC-SMOKE; [18]. The project
is registered on the International Prospective Register of
Systematic Reviews (PROSPERO) (CRD42015025251)
and the Open Science Framework (https://osf.io/23hfv/).
The completed Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) checklist is in
Supporting information, Appendix A [21].
Eligibility
The Cochrane Tobacco Addiction Group Specialized Reg-
ister was searched on 1 November 2015 for RCTs
assessing the impact of behavioral interventions (with
or without smoking cessation medication) on biochemi-
cally verified smoking cessation at 6 months or longer.
Trials without biochemically verified outcomes were ex-
cluded to protect against multiple sources of bias
[22,23]. Trials were excluded if they were published be-
fore 1996, were not reported in English (as resources for
translation of documentation were not available) or in
peer-reviewed journals, or if participants were aged un-
der 18 years. Trials published before 1996 were ex-
cluded because older trials of behavioral interventions
are less relevant in a continually changing social and
policy environment, and because preliminary work indi-
cated that it was very difficult to retrieve the required
materials from authors of trials published beyond
20 years earlier. The comparator groups included in
the present analyses were the single least intensive
groups in each RCT (i.e. one comparator group per
RCT), which could have included no support, medica-
tion, usual care or comparator interventions introduced
by the researchers. Detailed methods are described in
the Intervention and Comparison group support pro-
vided in SMOKing cEssation (IC-SMOKE) protocol [18].
Procedure
Data were first extracted from published materials (e.g. pri-
mary articles, appendices, protocols, intervention develop-
ment papers). A comprehensive procedure of contacting
authors of all included trials was then executed
to retrieve additional, unpublished materials [24].
First/corresponding authors were contacted by e-mail (in-
cluding several reminders), followed-up by telephone as
1We use the term ‘comparator group’ in recognition of the fact that many of these groups receive (comparator) interventions.
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required. If the first/corresponding author did not reply or
was unable to help, the second/last authors were
contacted, followed by middle authors, as required.
Authors were asked to provide additional materials on
the intervention provided to their comparator group (e.g.
manuals, practitioner training materials, self-help mate-
rials, website content) and to complete a comparator
intervention checklist. The comparator intervention
checklist (https://osf.io/e834t/) was a purpose-built
questionnaire capturing smoking cessation activities
(Javornik et al., unpublished). We developed it based on in-
ternational stop smoking treatment manuals, input from
advisory board members (of smokers/ex-smokers, smoking
cessation professionals and policymakers), expertise within
the study team and smoking cessation examples provided
in previous BCT taxonomies. A similar approach was
shown to be reliable and valid in the previous HIV medica-
tion adherence systematic review [16].
The active content provided to comparator groups
(namely, BCTs and smoking cessationmedications) was ex-
tracted from the above-described materials. Two re-
searchers independently and reliably [25] used the BCT
taxonomy (BCTTv1; Supporting information, Appendix
A) [19]—with one BCT added and one BCT removed—to
code the presence/absence of 93 individual BCTs, the be-
havior targeted by each BCT (smoking cessation behaviors:
making a quit attempt, remaining abstinent; adjuvant be-
haviors: adhering to medication, engaging in treatment)
and whether the BCT delivery was personalized (i.e. indi-
vidually tailored or requiring active recipient involvement).
Examples of BCTs are reducing prompts or cues that might
trigger smoking, considering the pros and cons of quitting
and verbally persuading the person that they are capable
of quitting. Following retrieval and coding of all available
materials, the extent to which these materials comprehen-
sively described the active intervention content was deter-
mined using independent double coding [see Supporting
information, Appendix A for the decision model used; prev-
alence and bias-adjusted kappa (PABAK) = 0.79]. The
comparator interventions were labelled as well described
if the coders judged the materials to be of sufficient detail
and clarity to identify all or almost all the BCTs that were
delivered to that comparator group. Finally, comparators
were also coded as to whether the BCTs were primarily de-
livered in writing (digital/print) or by a person (face-to-face
or via telephone).
Data analysis
The a priori prepared analysis plan was published on the
Open Science Framework before conducting the analyses
(https://osf.io/23hfv/). Analyses were conducted using
themetafor package in R [26]. The analysis script and data
(https://osf.io/gk56j/) are also available on the Open Sci-
ence Framework. Multi-level, mixed-effects meta-
regressionmodels were used to examine the association be-
tween comparator intervention content and (logit-trans-
formed) smoking cessation rates. Outcome time points
were all those at 6 months (± 1 month)2 post-
randomization or later (i.e. multiple time-points per study
were permitted). Multiple outcome time-points were in-
cluded, as this provides a more thorough synthesis of the
available evidence than would be afforded by omitting all
data other than those of a single time-point. The model in-
cluded random intercepts for studies (to account for
between-study heterogeneity),3 correlated random effects
for multiple observations (i.e. logit rates) within studies
with a continuous time autoregressive structure (to ac-
count for heterogeneity in multiple observations corre-
sponding to the same group) and correlated sampling
errors for multiple observations within studies (to account
for the dependency between multiple observations corre-
sponding to the same group). For the sampling errors, we
conservatively assumed an autocorrelation coefficient of
ρ = 0.9 for a lag of 1 month. The smoking cessation rates
extracted from the studies were based on intent-to-treat
analyses with missing responses treated as smokers (as-
sumption: missing = smoking; [27]). Only those compara-
tor groups rated as well described were included in the
primary analyses. Various sensitivity analyses were con-
ducted, including fitting the models while controlling for
attrition, including all comparator groups, and using ro-
bust variance estimation [28]. These are described in full
in the analysis plan.
In the first primary model, smoking cessation rates
were regressed on the degree of behavioral support (num-
ber of smoking cessation BCTs; i.e. those targeting quitting
or abstinence) and the provision of medication (0 = no,
1 = yes; model 1). In the second primary model, smoking
cessation rates were regressed on the number of personal-
ized BCTs, the number of non-personalized BCTs and the
provision of medication (model 2).
In the secondary analyses, we first examined (models 3
and 4) whether the effect of BCTs on smoking cessation de-
pends on the mode of delivery [i.e. whether comparator in-
terventionswere primarily delivered inwriting (= 0) or by a
person (= 1)] by adding a mode of delivery main effect and
its interaction with smoking cessation BCTs to models 1
and 2. To investigate the additional value of supporting
the adjuvant behaviors (models 5 and 6), we added num-
ber of treatment engagement BCTs, number of medication
adherence BCTs and the interaction between medication
2To allow for variation between studies in the exact time at which follow-up assessments were conducted, we allowed all time-points at 5months or later to be
included.
3As each study contributed a single comparator group to the analyses, study and group are synonymous in this context.
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provision and number of medication adherence BCTs (as
adherence BCTs should primarily benefit people who were
provided with medication) to models 1 and 2, respectively.
Exploratory analyses were also conducted; namely, to in-
vestigate potential differences over time, differences by
quitting versus abstinence BCTs, and interactions between
smoking cessation BCTs and medication in determining
smoking cessation. The results of these are described in
Supporting information, Appendix B.
All analyses were controlled for potential confounding
variables that we identified through literature review and
input from our advisory board panel [29–31]. These con-
trol variables were: (1) mean age (in years), (2) mean nic-
otine dependence (using the Fagerström Test for Nicotine
Dependence; theoretical range: 0–10; missing values im-
puted based on cigarettes per day, where available [32]),
(3) length of follow-up (coded in 6-month units to facilitate
interpretation; log-transformed to pre-emptively avoid any
undue influence of a few very long follow-up assessments),
(4) cotinine verification [1 = yes, 0 = no, where no includes
less stringent biochemical verification types, such as ex-
haled carbon monoxide (CO)] and (5) type of abstinence
assessed (1 = sustained, 0 = point prevalence). The selec-
tion of these variables is discussed further in the analysis
plan.
Future research
Smoking is a leading cause of premature mortality, disease
and health-care expenditures [1,2], and the current study
suggests that existing smoking cessation intervention re-
search might be overlooking an important source of clini-
cal, and possibly statistical, heterogeneity. We are
currently conducting analyses to determine if and how
the observed variability in comparator groups impacts con-
clusions about the relative effectiveness of different types of
interventions, with the goal of producingmore accurate es-
timates of intervention effects (https://osf.io/khm8u/). Fur-
ther, as the link between comparator interventions and
outcomes has now been established in both the HIV medi-
cation adherence [16,17] and smoking cessation domains,
it will be important to investigate whether similar effects
are occurring in other domains of behavioral interventions,
and complex interventions more generally. To enable this,
it is essential that trial authors provide detailed descriptions
of their comparator interventions, as published descrip-
tions are often incomplete [24,33–36]. New tools such as
the Addiction Journal’s Paper Authoring Tool might facili-
tate this [37].
The results of this study highlight avenues for research
into improving usual care for smoking cessation. Re-
searchers could investigate whether adding additional
BCTs—especially BCTs delivered by a person—into existing
programmes leads to higher rates of smoking cessation.
Further, to operationalize comparator group support we
took a pragmatic approach using a simple sum score of
BCTs. To provide better guidance on which support is most
effective, it will be important to investigate which combina-
tions of BCTs are associated with the highest smoking ces-
sation rates (as we are currently doing: https://osf.io/
m5vea/). Finally, it will be important to investigate how
BCTs can be best translated to be delivered in writing (dig-
ital and/or print), as we did not find evidence of an associ-
ation with smoking cessation when delivered through
these mediums. At present, such interventions produce
small increases in smoking cessation [9,10] and identifying
which components of these aremost effective could help us
increase the effectiveness of these interventions.
RESULTS
Study identification
Initially, 5992 records were identified (Fig. 1). Following
screening and eligibility assessment, 142 unique trials
were included (see Supporting information, Appendix B
for a list of included studies); 110 of 142 (77%) comparator
groups were rated as well described, after retrieving addi-
tional information from authors on 93 of 142 (65%) of
comparator groups. Of the 110 well-described comparator
groups, complete data on all primary predictor and control
variables were available for 104 groups, and these are
analysed here. This included n = 23706 participants and
161 time-points ranging from 22 to 130 weeks post-
randomization (one study contributed five time-points,
three contributed four time-points, six contributed three
time-points, 32 contributed two time-points and the re-
maining 62 contributed a single time-point).
Variability in behavioral and pharmacological support
There was considerable variability between the 104 com-
parator groups in the number of smoking cessation BCTs
delivered (mean = 15.97, SD = 13.54, range = 0–45),
number of personalized smoking cessation BCTs delivered
(mean = 3.12, SD = 3.93, range = 0–16) and provision of
medication (43%). The most commonly delivered smoking
cessation BCTs were unspecified social support, tell to act
and information about health consequences (delivered to
81, 67 and 67% of comparator groups, respectively). The
most commonly delivered personalized smoking cessation
BCTs were unspecified social support, behavioral goal-
setting and reducing exposure to cues (delivered to 50, 27
and 23% of comparator groups, respectively).
Further, when grouping the comparators in categories
typically used in systematic reviews of smoking cessation
trials, variability in the number of BCTs delivered to ‘no be-
havioral support’ comparator groups was low
(mean = 1.38, SD = 2.48, range = 0–9, k = 21), but
1610 Nicola Black et al.
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considerable variability remained within the other catego-
ries: ‘self-help’ (mean = 18.00, SD = 8.54, range = 5–32,
k = 10), ‘brief advice’ (mean = 12.11, SD = 11.08,
range = 0–45, k = 37), ‘extended counselling’
(mean = 27.89, SD = 9.99, range = 5–43, k = 36) and
‘usual care’ (mean = 12.07, SD = 13.50, range = 0–45,
k = 28 [5]). Hence, even within these typical categories,
some comparator groups receive little to no support,
whereas others receive extensive support.
Association between intervention active content and
smoking cessation
Provision of smoking cessation medication and more
smoking cessation BCTs predicted higher smoking cessa-
tion rates (model 1, Table 1). The BCT-smoking cessation
association seemed to be driven both by personalized BCTs
and non-personalized BCTs, as these associations with
cessation rates were not significantly different
(P = 0.400; model 2). Given that these two predictors were
correlated (r = 0.49, P < 0.001), we re-ran the models
with each predictor separately, which gave slightly larger
differences in effect sizes and smaller P-values (personal-
ized: B = 0.057, P = 0.004; non-personalized:
B=0.022, P=0.002), suggesting that both variables were
competing for the same variance. These results suggest
that delivering more personalized and non-personalized
BCTs, as well as smoking cessation medication, predicts
higher smoking cessation rates in these comparator
groups.
Interaction between mode of delivery and BCTs in
predicting smoking cessation
Whether smoking cessation BCTs aremore strongly predic-
tive of smoking cessation when delivered by a person than
when delivered in writing (digital and/or print) was tested
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. BCTs = behavior change techniques
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in models 3 and 4. The association between smoking cessa-
tion rates and number of BCTs delivered was evident for
those BCTs delivered by a person (B = 0.022, P = 0.001),
but not those delivered in writing (B = 0.020,
P = 0.452); although the direct interaction test did not
suggest that these association differed (model 3).
When BCTs were personalized, the association with
higher smoking cessation was again evident when they
were delivered by a person (B = 0.055, P = 0.013), but
not when delivered in writing (B = 0.131, P = 0.052),
and these associations were significantly different (model
4). There was no evidence that non-personalized BCTs
delivered in writing (B = 0.031, P = 0.416) or by a person
(B = 0.015, P = 0.072) predicted smoking cessation.
Together, these results show that personalized and
person-delivered BCTs are associated with higher smoking
cessation, with no support found for non-personalized
BCTs or those delivered in writing.
Association between BCTs targeting adjuvant behaviors
and smoking cessation
The associations between BCTs targeting adjuvant
behaviors and smoking cessation rates were tested in
models 5 and 6. Higher smoking cessation rates were
predicted by provision of more BCTs to engage the
participant in the treatment (models 5 and 6), but not by
more BCTs to aid medication adherence (model 5:
B = 0.022, P = 0.698; model 6: B = 0.011,
P = 0.861 among those groups who were provided medi-
cation). The association between number of treatment
engagement BCTs and smoking cessation was attenuated
by the removal of one influential case (model 5:
B = 0.182, P = 0.081; model 6: B = 0.170, P = 0.115).
The comparator group in this study [38] received a large
number of treatment engagement BCTs relative to all other
comparator groups (8 versus range of others: 0–3), and
this seemed to determine the results of this analysis.
Estimated smoking cessation rates at different levels of
behavioral and pharmacological support
The predicted impact of varying levels of behavioral and
pharmacological support on smoking cessation rates is
shown in Fig. 2. As seen, our models predicted that, on av-
erage, 8% of those who received no behavioral or pharma-
cological support will be abstinent. If participants received
45 BCTs (the observed maximum), then the predicted ces-
sation rate increased to 18%. If participants also received
smoking cessation medication, this rate increased to
23%. Similarly, if participants received 16 personalized,
person-delivered BCTs (the observed maximum), the pre-
dicted cessation rate was 18% without medication and
22% with medication. Note the different scales on the x-
axes in Fig. 2a versus Fig. 2b, illustrating that similar
smoking cessation rates might be achieved using fewer




This study examined the variability in, and effectiveness of,
the active content of interventions (namely, BCTs and
smoking cessation medications) provided to comparator
groups in RCTs of behavioral interventions for smoking ces-
sation. The active content varied considerably among all
comparator groups and within typical categories of com-
parator groups (e.g. usual care, brief advice). Further, deliv-
ery of smoking cessation medication and more behavioral
support predicted higher smoking cessation rates in these
comparator groups. The predicted effect of this variability
was a 15%-point absolute difference in cessation rates be-
tween comparator groups, with the least and most inten-
sive comparator interventions predicting 8 and 23%
cessation, respectively. This difference between comparator
groups is greater than the typical differences seen between
experimental and comparator groups in smoking cessation
trials [4,5,39].
This study replicates and extends earlier work, in which
the authors raised the issue of variability in interventions
delivered to comparator groups of behavioral trials and its
implications for interpreting and comparing effect sizes
[16,17]. This work was performed in the area of HIV med-
ication adherence interventions in a small set of only usual
care comparator groups. That these results have now also
been obtained for a substance use/addictive behavior
(smoking) in a large set of studies with multiple categories
of comparator groups clearly supports the idea that readers
and systematic reviewers need to consider variability in
comparator interventions when interpreting, comparing
and generalizing trial effect sizes [17,40].
This study also found support for the potential role of
BCTs in increasing smoking cessation rates, particularly
when personalized and delivered by a person, and did not
find evidence that the effect of these BCTs on cessation de-
clines over time (Supporting information, Appendix B).
This adds to existing literature, which has shown stronger
intervention effects when interventions are delivered, at
least in part, by a person (compared to self-help alone)
and when interventions are tailored to the participant
[5,41–43]. This study also adds to the mixed, broader
health behavior change literature, which has found some
positive relationships between the number of BCTs used
and smoking cessation [44] and other behaviors (e.g.
[45–47]) but which, overall, typically finds non-significant
relationships with smoking cessation [48] and other out-
comes (e.g. [36,49–57]). The strengths of our
Comparator group variability 1613
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methodology (retrieval of unpublished materials, restric-
tion of analyses to well-described studies) might have in-
creased the accuracy of our BCT data. Along with the
much larger number of included studies, this would in-
crease power to detect the BCTs–cessation relationship.
Strengths and limitations
The key strengths of this study are, first, the retrieval of ex-
tensive, unpublished materials describing comparator in-
terventions from authors and the restriction of analyses
to well-described comparators. Secondly, the inclusion of
a priori specified confounders and the observed dose–
response relationship increase confidence in a potential
causal link between comparator interventions and out-
comes [58]. The key limitation is that analyses were corre-
lational and unaddressed confounders could be driving the
associations. Other intervention factors, such as frequency
or duration of interpersonal contact, could influence out-
comes. Nonetheless, if this is the case, the implication that
variability in comparator interventions warrants consider-
ation remains unchanged. Further, we included only En-
glish language publications, meaning that our review
does not cover comparator groups from RCTs published ex-
clusively in other languages. Finally, our BCT variable was
a sum score, which therefore assumed that all BCTs are
equally effective; this may not be the case. However, in
the absence of evidence of the effectiveness of each BCT
in this context, this pragmatic approach was judged to be
most suitable.
Implications for policy and practice
Policymakers and practitioners use publications about tri-
als and systematic reviews to evaluate which interventions
to fund and implement. Our results indicate that, when
Figure 2 Predicted smoking cessation rates across the observed range of (a) total behavior change techniques (BCTs) and (b) personalized, person-
delivered BCTs. Dotted lines represent 95% confidence intervals. Estimated smoking cessation rates are computed at 6-month follow-up, non-cotin-
ine verified, point prevalence abstinence and mean levels of age and nicotine dependence. [Colour figure can be viewed at wileyonlinelibrary.com]
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doing so, it is key to consider against what comparators
these interventions have been tested. We observed large
(15% points) predicted differences in smoking cessation be-
tween comparator groups that were associated with the
level of support received. This variability could make some
experimental interventions appear much stronger than
others whereas, in fact, this might have nothing to do with
the experimental interventions; instead, it might be due to
one trial having a minimal and another trial an intensive
comparator intervention. Currently used methods for ac-
counting for comparator group variability (i.e. separating
meta-analyses by categories of comparator groups) may
go some distance, but as variability in active content within
commonly used categories is substantial this is unlikely to
fully address the issue. Hence, we recommend that re-
searchers, policymakers and practitioners ensure that full
information on the comparator interventions is available
and considered when interpreting, comparing and general-
izing intervention effects and when making decisions on
which services to fund and implement.
CONCLUSIONS
Interventions provided to comparator groups in smoking
cessation trials vary substantially and predict cessation
rates in these groups. This variability should be considered
when synthesizing, interpreting, comparing or generaliz-
ing intervention effects.
Systematic review registration
PROSPERO (CRD42015025251) and the Open Science
Framework (analysis plan: https://osf.io/24pzj/).
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